IRVINE, Calif.--(BUSINESS WIRE)--

California Stem Cell, Inc. (CSC) has announced the completion of an internal study demonstrating that the companys proprietary immunotherapy manufacturing process can be applied to multiple cancer types. Originally developed for late stage metastatic melanoma, the platform tissue culture technology has also been shown to work with tumor tissues from hepatocellular carcinoma, ovarian cancer, glioblastoma multiforme, and other solid tumor cancers.

The unique principle supporting CSCs cancer immunotherapeutic approach is purification of tumor stem cells isolated from a patients own tumor tissue, to use as an antigenic source. While prior companies processes typically took months and often yielded unreliable or unusable materials, CSC has standardized its platform technology for reproducibility, resulting in optimized high cell yields, and efficient and scalable manufacturing.

The companys proprietary stem cell culturing technologies, performed under cGMP conditions, have resulted in a consistent production time of less than 8 weeks, with a 100% success rate in generating lines with potential applicability to a broad range of cancer types.

Such significant improvements in the manufacturing time and success rate are critical when working with late stage cancers that typically have a short window for treatment, said Gabriel Nistor, M.D., CSC Vice President of Research and Development. The improvements allowed us to test our proprietary manufacturing methods on a broader range of devastating cancer types, with encouraging results.

CSC recently submitted a Phase III protocol to the U.S. Food and Drug Administration to explore efficacy of its cancer stem cell-based treatment for recurrent stage III and stage IV melanoma. The company is also completing a Phase I clinical study in liver cancer, and preparing to submit a Phase II clinical study in ovarian cancer.

About California Stem Cell

California Stem Cell Inc. (CSC) is an Irvine, CA-based company focused on the development of stem cell-based therapies for metastatic cancers, spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS, or Lou Gehrigs Disease).

CSC has proprietary methods to generate human stem cell lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and cGMP processes.

Follow us on Twitter: http://twitter.com/castemcell

Excerpt from:
Cancer Immunotherapy Platform Targets Broad Range of Metastatic Cancers